|
|
|
| Effect of Ticagrelor on Unstable Angina Pectoris of Coronary Heart Disease on Human Plasma Lipoprotein-Related Phospholipase A2 and Cardiac Function |
| WANG Jing, ZHANG Yingqiang, XU Yanjuan, et al |
| Nanjing Central Hospital, Jiangsu Nanjing 210018, China |
|
|
|
|
Abstract Objective: To investigate the effect of ticagrelor on the plasma lipoprotein-related phospholipase A2 (Lp-PLA2) and cardiac function in patients with unstable angina pectoris of coronary heart disease. Methods: A total of 80 patients admitted to our hospital from July 2018 to May 2020 were selected and randomly divided into control group and study group with 40 cases in each by the random number table method. The control group received conventional treatment, and the study group was taking ticagrelor antiplatelet therapy on the basis of control group. The plasma Lp-PLA2, platelet indexes and cardiac function indexes were tested and compared and analyzed after the treatment. Results: After treatment, the maximum platelet aggregation rate of Lp-PLA2 in the study group was significantly lower than that of the control group (P<0.05), and the effective platelet inhibition rate was significantly higher than that of the control group (P<0.05); compared with the control group, SV, FS, EF and other cardiac function indexes of the study group after treatment were significantly higher, and LVDd was significantly lower (P<0.05); the clinical treatment effect of angina pectoris in the study group was significantly better than that of the control group. The results of multivariate logistic regression analysis showed that LpPLA2 was an independent risk factor for the efficacy of angina pectoris, and SV was a protective factor for the efficacy of angina pectoris. Conclusion: Ticagrelor can effectively inhibit platelet aggregation in patients with unstable angina pectoris of coronary heart disease, enhance the antiplatelet coagulation effect, effectively improve the heart function of patients, and the therapeutic effect is more significant. The therapeutic effect of angina pectoris is related to multiple factors such as Lp-PLA2 and SV.
|
|
|
|
|
|
[1] 王阶,陈光.冠心病稳定型心绞痛中医诊疗专家共识[J].中医杂志,2018,59(5):447~450.
[2] 雷振民,汪希.冠心病患者双联抗血小板治疗中上消化道出血影响因素分析[J].实用临床医药杂志,2020,24(14):112~114.
[3] 诸帆,章琪.替格瑞洛对冠心病介入治疗患者临床疗效凝血功能及血小板聚集的影响研究[J].中国基层医药,2019,(18):2227~2230.
[4] 刘治军.2012年ACCF/AHA对不稳定心绞痛/非ST段抬高的心肌梗死患者管理的指南更新简介[J].药品评价,2013,10(22):19~24,26~27.
[5] 中华心血管病杂志编辑委员会.不稳定性心绞痛诊断和治疗建议中华医学会心血管病学分会[J].中华心血管病杂志,2000,28(6):409.
[6] 夏杨,李强,张惠军.丹参多酚酸盐注射液联合二丁酰环磷腺苷钙治疗不稳定性心绞痛的临床疗效[J].中华老年心脑血管病杂志,2019,21(3):254~257.
[7] 张永叶.冠心病患者生活质量与各影响因素的相关性[J].护理实践与研究,2020,17(15):71~72.
[8] 贾婷婷,苏和,张瑞芬,等.不稳定性心绞痛中医诊疗指南临床应用评价研究[J].中医药信息,2019,36(4):48~51.
[9] 王素玲,贾永平,何丽娇.GRACE评分联合血清Lp-PLA2、NT-proBNP水平监测在急性心肌梗死患者PCI术后MACE事件预测中的应用[J].河北医学,2019,25(5):737~742.
[10] 盛和静,郑祥.冠心病合并糖尿病发生阿司匹林抵抗的危险因素分析[J].浙江临床医学,2020,22(6):857~858.
[11] 薛恩忠,李慧婷,刘春丽.加味丹参饮联用替格瑞洛对冠心病心脏功能、hs-CRP、NT-proBNP及Fib的影响[J].西部中医药,2019,32(6):83~85.
[12] 杨亮.替格瑞洛治疗急性冠脉综合征后血尿酸水平对心脑血管不良事件再发生的影响[J].蚌埠医学院学报,2018,43(8):1052~1054. |
|
|
|
2021, Vol. 27 
